David J. Vocadlo
David Vocadlo was born in Brantford, Ontario. He obtained a BSc (Hon) in combined Chemistry and Biochemistry at the University of British Columbia (UBC). David completed his PhD in Chemistry at UBC studying carbohydrate synthesis and enzymology with Steve Withers. He was a CIHR postdoctoral fellow at the University of California at Berkeley with Carolyn Bertozzi developing proteomics probes for protein glycosylation. He is currently cross appointed as Professor in the Department of Chemistry and Department of Molecular Biology and Biochemistry and is a Tier I Canada Research Chair in Chemical Biology. He and his team has been recognized with several awards including the EWR Steacie Memorial Fellowship, Canada's Top 40 Under 40, the Horace S. Isbell Award of the American Chemical Society, Carbohydrate Research Award of the International Carbohydrate Organization, and the Boehringer-Ingleheim Research Excellence Award. David was named an inaugural fellow of the College of New Scholars and Scientists of the Royal Society of Canada. (RSC) He is a co-founder of Alectos Therapeutics which was founded on technology licensed from SFU from the Laboratory of Chemical Glycobiology and which has partnered with Merck to advance OGA inhibitors into the clinic.